William R Sellers

William R Sellers

UNVERIFIED PROFILE

Are you William R Sellers?   Register this Author

Register author
William R Sellers

William R Sellers

Publications by authors named "William R Sellers"

Are you William R Sellers?   Register this Author

100Publications

5478Reads

6Profile Views

Big Data Approaches for Modeling Response and Resistance to Cancer Drugs.

Annu Rev Biomed Data Sci 2018 Jul 25;1:1-27. Epub 2018 Apr 25.

Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-biodatasci-080917-013350DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6655478PMC
July 2018

Mechanism of Action and Clinical Impact of Ribociclib-Response.

Clin Cancer Res 2017 09;23(18):5658

The Broad Institute and Dana-Farber Cancer Institute, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-1819DOI Listing
September 2017

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

Cell 2017 Jul;170(3):577-592.e10

Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.07.005DOI Listing
July 2017

Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.

J Med Chem 2016 09 12;59(17):7773-82. Epub 2016 Jul 12.

Global Discovery Chemistry, ‡Oncology Disease Area, §Center for Proteomic Chemistry, ∥Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, and ⊥Chemical and Pharmaceutical Profiling, Novartis Pharmaceuticals , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.6b00680DOI Listing
September 2016

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.

EMBO Rep 2015 Mar 13;16(3):280-96. Epub 2015 Feb 13.

Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15252/embr.201439949DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364868PMC
March 2015

Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.

Cancer Res 2014 Jun 18;74(12):3294-305. Epub 2014 Apr 18.

Authors' Affiliations: Oncology Department, Novartis Institutes for BioMedical Research; Zalicus Inc., Cambridge; and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0138-TDOI Listing
June 2014

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Mol Cancer Ther 2014 May 7;13(5):1117-29. Epub 2014 Mar 7.

Authors' Affiliations: Novartis Institutes for BioMedical Research, Disease Area Oncology; Novartis Institutes for BioMedical Research, Global Discovery Chemistry; Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry; Novartis Pharma AG, Oncology Translational Medicine, Basel, Switzerland; Novartis Pharma AG, Oncology Translational Medicine; Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Cambridge, Massachusetts; and Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Shangai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0865DOI Listing
May 2014

An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.

Cancer Res 2013 Oct 8;73(19):6024-35. Epub 2013 Aug 8.

Authors' Affiliations: Novartis Institutes for Biomedical Research, Cambridge, Massachusetts; Departments of Medicine and Cancer Biology; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; MorphoSys AG, Martinsried, Germany; and Genomics Institute of the Novartis Research Foundation, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924863PMC
October 2013

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Cancer Discov 2013 Sep 10;3(9):1030-43. Epub 2013 Jul 10.

1Oncology Disease Area, 2Department of Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-13-0142DOI Listing
September 2013

Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer.

Nat Med 2013 May;19(5):538-40

Novartis Institute for Biomedical Research, Emeryville, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3195DOI Listing
May 2013

M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth.

Proc Natl Acad Sci U S A 2013 Jan 24;110(2):489-94. Epub 2012 Dec 24.

Disease Area Oncology, Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1212780110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545759PMC
January 2013

The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.

Mol Cancer Ther 2012 Mar 12;11(3):730-9. Epub 2012 Jan 12.

Novartis Institutes for Biomedical Research, 4560 Horton Street, Emeryville, CA 94608, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0667DOI Listing
March 2012

A blueprint for advancing genetics-based cancer therapy.

Cell 2011 Sep;147(1):26-31

Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2011.09.016DOI Listing
September 2011

Advances in the preclinical testing of cancer therapeutic hypotheses.

Nat Rev Drug Discov 2011 03;10(3):179-87

Novartis Institutes For BioMedical Research, Oncology Research and Oncology Translational Medicine, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd3385DOI Listing
March 2011

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

Cancer Res 2010 Sep 10;70(17):6804-14. Epub 2010 Aug 10.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-0409DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178450PMC
September 2010

An oncogenic role for ETV1 in melanoma.

Cancer Res 2010 Mar 16;70(5):2075-84. Epub 2010 Feb 16.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-3092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846410PMC
March 2010

p85 Associates with unphosphorylated PTEN and the PTEN-associated complex.

Mol Cell Biol 2009 Oct 27;29(19):5377-88. Epub 2009 Jul 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.01649-08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747981PMC
October 2009

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

Cancer Res 2009 May 28;69(10):4286-93. Epub 2009 Apr 28.

Novartis Institutes for BioMedical Research, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-4765DOI Listing
May 2009

Linking somatic genetic alterations in cancer to therapeutics.

Curr Opin Cell Biol 2009 Apr 26;21(2):304-10. Epub 2009 Mar 26.

Oncology Disease Area, Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095506740900048
Publisher Site
http://dx.doi.org/10.1016/j.ceb.2009.02.001DOI Listing
April 2009

Single-vector inducible lentiviral RNAi system for oncology target validation.

Cell Cycle 2009 Feb 25;8(3):498-504. Epub 2009 Feb 25.

Oncology Research, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.8.3.7701DOI Listing
February 2009

PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression.

Mol Cell Biol 2008 May 10;28(10):3281-9. Epub 2008 Mar 10.

Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://mcb.asm.org/cgi/doi/10.1128/MCB.00310-08
Publisher Site
http://dx.doi.org/10.1128/MCB.00310-08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423144PMC
May 2008

SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.

Nucleic Acids Res 2008 Apr 27;36(7):2446-56. Epub 2008 Feb 27.

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gkn089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2367734PMC
April 2008

Major copy proportion analysis of tumor samples using SNP arrays.

BMC Bioinformatics 2008 Apr 21;9:204. Epub 2008 Apr 21.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, 3 Blackfan Circle, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2105-9-204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375907PMC
April 2008

Identification of prostate cancer modifier pathways using parental strain expression mapping.

Proc Natl Acad Sci U S A 2007 Nov 31;104(45):17771-6. Epub 2007 Oct 31.

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0708476104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077015PMC
November 2007

A 2-Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome.

Am J Med Genet A 2007 Aug;143A(15):1692-8

Howard Hughes Medical Institute, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajmg.a.31776DOI Listing
August 2007

Mechanistic insights into maintenance of high p53 acetylation by PTEN.

Mol Cell 2006 Aug;23(4):575-87

Department of Biochemistry, University of California, Riverside, Riverside, California 92521, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2006.06.028DOI Listing
August 2006